Small Cell Lung Carcinoma Cells Depend on KIF11 for Survival.
Yuji SakumaSachie HiraiMiki YamaguchiMasashi IdogawaPublished in: International journal of molecular sciences (2024)
Few efficacious treatment options are available for patients with small cell lung carcinoma (SCLC), indicating the need to develop novel therapeutic approaches. In this study, we explored kinesin family member 11 (KIF11), a potential therapeutic target in SCLC. An analysis of publicly available data suggested that KIF11 mRNA expression levels are significantly higher in SCLC tissues than in normal lung tissues. When KIF11 was targeted by RNA interference or a small-molecule inhibitor (SB743921) in two SCLC cell lines, Lu-135 and NCI-H69, cell cycle progression was arrested at the G2/M phase with complete growth suppression. Further work suggested that the two cell lines were more significantly affected when both KIF11 and BCL2L1, an anti-apoptotic BCL2 family member, were inhibited. This dual inhibition resulted in markedly decreased cell viability. These findings collectively indicate that SCLC cells are critically dependent on KIF11 activity for survival and/or proliferation, as well as that KIF11 inhibition could be a new strategy for SCLC treatment.
Keyphrases
- cell cycle
- small molecule
- single cell
- gene expression
- cell death
- cell therapy
- cell proliferation
- induced apoptosis
- signaling pathway
- stem cells
- cell cycle arrest
- oxidative stress
- big data
- machine learning
- artificial intelligence
- mesenchymal stem cells
- bone marrow
- anti inflammatory
- pi k akt
- nucleic acid
- replacement therapy